Leerink Partners initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a research report released on Thursday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $16.00 target price on the specialty pharmaceutical company’s stock.
Other research analysts also recently issued reports about the stock. StockNews.com assumed coverage on shares of Tenax Therapeutics in a research report on Thursday, September 26th. They set a “sell” rating on the stock. Guggenheim initiated coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, William Blair began coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.67.
View Our Latest Stock Analysis on Tenax Therapeutics
Tenax Therapeutics Price Performance
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last released its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, beating the consensus estimate of ($1.99) by $0.16. On average, equities analysts anticipate that Tenax Therapeutics will post -6.75 EPS for the current fiscal year.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Featured Articles
- Five stocks we like better than Tenax Therapeutics
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- The 3 Best Retail Stocks to Shop for in August
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.